Position in TRLV
as of Jun 30, 2026
· filed Aug 12, 2026
Position Value
$71,827
New position
Shares Held
7,307
first reported quarter
Ownership
0.004%
of shares outstanding
% of Portfolio
0.00%
of 13F equity value
Holder Rank
#81
of 125 holders
Holding Since
Jun 2026
1 quarter on record
Voting authority
Sole 1%
Shared 0%
None 99%
Position in Drug Manufacturers - Specialty & Generic
Healthcare · as of Jun 30, 2026NewEdge Advisors, LLC holds $12,323,215 across 27 Drug Manufacturers - Specialty & Generic names. TRLV ranks #11 (0.6% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | ZTS |
Zoetis Inc.
|
36,078 | $2,592,565 | |
| 2 | NBIX |
Neurocrine Biosciences Inc
|
12,619 | $2,126,806 | |
| 3 | UTHR |
UNITED THERAPEUTICS Corp
|
3,861 | $2,092,005 | |
| 4 | TEVA |
Teva Pharmaceutical Industries Ltd
|
37,994 | $1,287,236 | |
| 5 | HLN |
Haleon plc
|
133,508 | $1,245,629 | |
| 6 | HIMS |
Hims & Hers Health, Inc.
|
21,721 | $753,067 | |
| 7 | VTRS |
Viatris Inc
|
39,976 | $634,818 | |
| 8 | COLL |
Collegium Pharmaceutical, Inc
|
16,739 | $605,951 |
All Filings in TRLV
Export CSV
1 filing row on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $71,827 | 7,307 | Shares | Sole | 2026-08-12 | |
| No filing history on record for this holder in this stock. | ||||||